ID   UBP16_HUMAN             Reviewed;         823 AA.
AC   Q9Y5T5; A8MU43; B3KN13; B4DFV8; B4DY37; D3DSD9; Q53GP7; Q53HA0;
AC   Q5VKN8; Q8NEL3; Q9H3E6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 16 {ECO:0000255|HAMAP-Rule:MF_03062};
DE            EC=3.4.19.12 {ECO:0000255|HAMAP-Rule:MF_03062};
DE   AltName: Full=Deubiquitinating enzyme 16 {ECO:0000255|HAMAP-Rule:MF_03062};
DE   AltName: Full=Ubiquitin thioesterase 16 {ECO:0000255|HAMAP-Rule:MF_03062};
DE   AltName: Full=Ubiquitin-processing protease UBP-M;
DE   AltName: Full=Ubiquitin-specific-processing protease 16 {ECO:0000255|HAMAP-Rule:MF_03062};
GN   Name=USP16 {ECO:0000255|HAMAP-Rule:MF_03062}; ORFNames=MSTP039;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF CYS-205.
RX   PubMed=10077596; DOI=10.1073/pnas.96.6.2828;
RA   Cai S.-Y., Babbitt R.W., Marchesi V.T.;
RT   "A mutant deubiquitinating enzyme (Ubp-M) associates with mitotic
RT   chromosomes and blocks cell division.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2828-2833(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Grimbert P., Pawlak A., Sahali D.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANT
RP   HIS-141.
RC   TISSUE=Amygdala, Teratocarcinoma, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   HIS-141.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 139-823.
RC   TISSUE=Aorta;
RA   Liu B., Liu Y.Q., Wang X.Y., Zhao B., Sheng H., Zhao X.W., Liu S.,
RA   Xu Y.Y., Ye J., Song L., Gao Y., Zhang C.L., Zhang J., Wei Y.J.,
RA   Cao H.Q., Zhao Y., Liu L.S., Ding J.F., Gao R.L., Wu Q.Y., Qiang B.Q.,
RA   Yuan J.G., Liew C.C., Zhao M.S., Hui R.T.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PRELIMINARY FUNCTION, AND MUTAGENESIS OF CYS-205.
RX   PubMed=11753566; DOI=10.1038/sj.cdd.4400924;
RA   Mimnaugh E.G., Kayastha G., McGovern N.B., Hwang S.G., Marcu M.G.,
RA   Trepel J., Cai S.-Y., Marchesi V.T., Neckers L.;
RT   "Caspase-dependent deubiquitination of monoubiquitinated nucleosomal
RT   histone H2A induced by diverse apoptogenic stimuli.";
RL   Cell Death Differ. 8:1182-1196(2001).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY,
RP   SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-205.
RX   PubMed=17914355; DOI=10.1038/nature06256;
RA   Joo H.-Y., Zhai L., Yang C., Nie S., Erdjument-Bromage H., Tempst P.,
RA   Chang C., Wang H.;
RT   "Regulation of cell cycle progression and gene expression by H2A
RT   deubiquitination.";
RL   Nature 449:1068-1072(2007).
RN   [11]
RP   CHROMOSOMAL REARRANGEMENT.
RX   PubMed=18925961; DOI=10.1186/1471-2407-8-299;
RA   Gelsi-Boyer V., Trouplin V., Adelaide J., Aceto N., Remy V.,
RA   Pinson S., Houdayer C., Arnoulet C., Sainty D., Bentires-Alj M.,
RA   Olschwang S., Vey N., Mozziconacci M.-J., Birnbaum D., Chaffanet M.;
RT   "Genome profiling of chronic myelomonocytic leukemia: frequent
RT   alterations of RAS and RUNX1 genes.";
RL   BMC Cancer 8:299-299(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415 AND SER-552, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552 AND THR-554, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-415 AND
RP   SER-552, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   POSSIBLE INVOLVEMENT IN DOWN SYNDROME.
RX   PubMed=24025767; DOI=10.1038/nature12530;
RA   Adorno M., Sikandar S., Mitra S.S., Kuo A., Nicolis Di Robilant B.,
RA   Haro-Acosta V., Ouadah Y., Quarta M., Rodriguez J., Qian D.,
RA   Reddy V.M., Cheshier S., Garner C.C., Clarke M.F.;
RT   "Usp16 contributes to somatic stem-cell defects in Down's syndrome.";
RL   Nature 501:380-384(2013).
RN   [20]
RP   STRUCTURE BY NMR OF 22-143, AND ZINC-BINDING.
RX   PubMed=17512543; DOI=10.1016/j.jmb.2007.04.015;
RA   Pai M.-T., Tzeng S.-R., Kovacs J.J., Keaton M.A., Li S.S.-C.,
RA   Yao T.-P., Zhou P.;
RT   "Solution structure of the Ubp-M BUZ domain, a highly specific protein
RT   module that recognizes the C-terminal tail of free ubiquitin.";
RL   J. Mol. Biol. 370:290-302(2007).
CC   -!- FUNCTION: Specifically deubiquitinates 'Lys-120' of histone H2A
CC       (H2AK119Ub), a specific tag for epigenetic transcriptional
CC       repression, thereby acting as a coactivator. Deubiquitination of
CC       histone H2A is a prerequisite for subsequent phosphorylation at
CC       'Ser-11' of histone H3 (H3S10ph), and is required for chromosome
CC       segregation when cells enter into mitosis. In resting B- and T-
CC       lymphocytes, phosphorylation by AURKB leads to enhance its
CC       activity, thereby maintaining transcription in resting
CC       lymphocytes. Regulates Hox gene expression via histone H2A
CC       deubiquitination. Prefers nucleosomal substrates. Does not
CC       deubiquitinate histone H2B. {ECO:0000255|HAMAP-Rule:MF_03062,
CC       ECO:0000269|PubMed:10077596, ECO:0000269|PubMed:17914355}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000255|HAMAP-Rule:MF_03062, ECO:0000269|PubMed:17914355}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000255|HAMAP-Rule:MF_03062,
CC       ECO:0000269|PubMed:17914355}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305|PubMed:17914355}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q9Y5T5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y5T5-2; Sequence=VSP_036715;
CC       Name=3;
CC         IsoId=Q9Y5T5-3; Sequence=VSP_036714, VSP_036715;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q9Y5T5-4; Sequence=VSP_036713;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q9Y5T5-5; Sequence=VSP_036716;
CC   -!- TISSUE SPECIFICITY: Present in all the tissues examined including
CC       fetal brain, lung, liver, kidney, and adult heart, brain,
CC       placenta, lung, liver, skeletal muscle, kidney and pancreas.
CC       {ECO:0000269|PubMed:10077596}.
CC   -!- DOMAIN: The UBP-type zinc finger binds 3 zinc ions that form a
CC       pair of cross-braced ring fingers encapsulated within a third zinc
CC       finger in the primary structure. It recognizes the C-terminal tail
CC       of free ubiquitin.
CC   -!- PTM: Phosphorylated at the onset of mitosis and dephosphorylated
CC       during the metaphase/anaphase transition. Phosphorylation by AURKB
CC       enhances the deubiquitinase activity. {ECO:0000255|HAMAP-
CC       Rule:MF_03062, ECO:0000269|PubMed:10077596}.
CC   -!- DISEASE: Note=A chromosomal aberration involving USP16 is a cause
CC       of Chronic myelomonocytic leukemia. Inversion inv(21) (q21;q22)
CC       with RUNX1/AML1.
CC   -!- MISCELLANEOUS: USP16 may contribute to somatic stem cell defects
CC       observed in Down syndrome. USP16 is triplicated in Down syndrome
CC       and its overexpression may contribute to proliferation defects in
CC       stem cells. Reduction of USP16 levels results in increased
CC       proliferation capacity of Down syndrome fibroblasts
CC       (PubMed:24025767). {ECO:0000305|PubMed:24025767}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. USP16 subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03062}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG39290.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAG51175.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF126736; AAD20949.1; -; mRNA.
DR   EMBL; AY333928; AAR13293.1; -; mRNA.
DR   EMBL; AK023247; BAG51175.1; ALT_INIT; mRNA.
DR   EMBL; AK302247; BAG63599.1; -; mRNA.
DR   EMBL; AK294284; BAG57569.1; -; mRNA.
DR   EMBL; AK222681; BAD96401.1; -; mRNA.
DR   EMBL; AK222884; BAD96604.1; -; mRNA.
DR   EMBL; AL163249; CAB90432.1; -; Genomic_DNA.
DR   EMBL; AF129075; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09927.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09929.1; -; Genomic_DNA.
DR   EMBL; BC030777; AAH30777.1; -; mRNA.
DR   EMBL; AF113219; AAG39290.1; ALT_INIT; mRNA.
DR   CCDS; CCDS13583.1; -. [Q9Y5T5-1]
DR   CCDS; CCDS42912.1; -. [Q9Y5T5-2]
DR   RefSeq; NP_001001992.1; NM_001001992.1. [Q9Y5T5-2]
DR   RefSeq; NP_001027582.1; NM_001032410.1. [Q9Y5T5-1]
DR   RefSeq; NP_006438.1; NM_006447.2. [Q9Y5T5-1]
DR   RefSeq; XP_016883746.1; XM_017028257.1. [Q9Y5T5-1]
DR   RefSeq; XP_016883747.1; XM_017028258.1. [Q9Y5T5-2]
DR   RefSeq; XP_016883748.1; XM_017028259.1. [Q9Y5T5-2]
DR   RefSeq; XP_016883749.1; XM_017028260.1. [Q9Y5T5-4]
DR   RefSeq; XP_016883750.1; XM_017028261.1. [Q9Y5T5-4]
DR   UniGene; Hs.99819; -.
DR   PDB; 2I50; NMR; -; A=22-143.
DR   PDBsum; 2I50; -.
DR   ProteinModelPortal; Q9Y5T5; -.
DR   SMR; Q9Y5T5; -.
DR   BioGrid; 115848; 30.
DR   IntAct; Q9Y5T5; 4.
DR   STRING; 9606.ENSP00000334808; -.
DR   MEROPS; C19.021; -.
DR   iPTMnet; Q9Y5T5; -.
DR   PhosphoSitePlus; Q9Y5T5; -.
DR   BioMuta; USP16; -.
DR   DMDM; 6686071; -.
DR   EPD; Q9Y5T5; -.
DR   PaxDb; Q9Y5T5; -.
DR   PeptideAtlas; Q9Y5T5; -.
DR   PRIDE; Q9Y5T5; -.
DR   DNASU; 10600; -.
DR   Ensembl; ENST00000334352; ENSP00000334808; ENSG00000156256. [Q9Y5T5-1]
DR   Ensembl; ENST00000399975; ENSP00000382857; ENSG00000156256. [Q9Y5T5-2]
DR   Ensembl; ENST00000399976; ENSP00000382858; ENSG00000156256. [Q9Y5T5-1]
DR   GeneID; 10600; -.
DR   KEGG; hsa:10600; -.
DR   UCSC; uc002ymw.4; human. [Q9Y5T5-1]
DR   CTD; 10600; -.
DR   DisGeNET; 10600; -.
DR   GeneCards; USP16; -.
DR   H-InvDB; HIX0023011; -.
DR   HGNC; HGNC:12614; USP16.
DR   HPA; HPA021140; -.
DR   MIM; 604735; gene.
DR   neXtProt; NX_Q9Y5T5; -.
DR   OpenTargets; ENSG00000156256; -.
DR   PharmGKB; PA37240; -.
DR   eggNOG; KOG1873; Eukaryota.
DR   eggNOG; COG5560; LUCA.
DR   GeneTree; ENSGT00860000133682; -.
DR   HOVERGEN; HBG062704; -.
DR   InParanoid; Q9Y5T5; -.
DR   KO; K11844; -.
DR   OMA; FEMQSTK; -.
DR   OrthoDB; EOG091G01WT; -.
DR   PhylomeDB; Q9Y5T5; -.
DR   TreeFam; TF326075; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SIGNOR; Q9Y5T5; -.
DR   ChiTaRS; USP16; human.
DR   EvolutionaryTrace; Q9Y5T5; -.
DR   GeneWiki; USP16; -.
DR   GenomeRNAi; 10600; -.
DR   PRO; PR:Q9Y5T5; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000156256; -.
DR   CleanEx; HS_USP16; -.
DR   ExpressionAtlas; Q9Y5T5; baseline and differential.
DR   Genevisible; Q9Y5T5; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; TAS:ProtInc.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0016578; P:histone deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070537; P:histone H2A K63-linked deubiquitination; IMP:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0035522; P:monoubiquitinated histone H2A deubiquitination; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0045901; P:positive regulation of translational elongation; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; IPI:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IEA:InterPro.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 3.30.40.10; -; 1.
DR   HAMAP; MF_03062; UBP16; 1.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR030849; UBP16.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR001607; Znf_UBP.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF02148; zf-UBP; 1.
DR   SMART; SM00290; ZnF_UBP; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
DR   PROSITE; PS50271; ZF_UBP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cell cycle;
KW   Cell division; Chromatin regulator; Chromosomal rearrangement;
KW   Complete proteome; Hydrolase; Metal-binding; Mitosis; Nucleus;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Thiol protease; Transcription; Transcription regulation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    823       Ubiquitin carboxyl-terminal hydrolase 16.
FT                                /FTId=PRO_0000080643.
FT   DOMAIN      196    822       USP.
FT   ZN_FING      60    125       UBP-type. {ECO:0000255|HAMAP-
FT                                Rule:MF_03062}.
FT   ACT_SITE    205    205       Nucleophile.
FT   ACT_SITE    758    758       Proton acceptor. {ECO:0000255|HAMAP-
FT                                Rule:MF_03062}.
FT   METAL        24     24       Zinc 1.
FT   METAL        26     26       Zinc 1.
FT   METAL        48     48       Zinc 2.
FT   METAL        51     51       Zinc 2.
FT   METAL        74     74       Zinc 3.
FT   METAL        77     77       Zinc 3.
FT   METAL        82     82       Zinc 2.
FT   METAL        90     90       Zinc 2.
FT   METAL        94     94       Zinc 3.
FT   METAL       103    103       Zinc 3.
FT   METAL       116    116       Zinc 1.
FT   METAL       119    119       Zinc 1.
FT   MOD_RES     189    189       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     415    415       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99LG0}.
FT   MOD_RES     552    552       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     554    554       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   VAR_SEQ       1    310       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036713.
FT   VAR_SEQ       1     20       MGKKRTKGKTVPIDDSSETL -> MGSVAV (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036714.
FT   VAR_SEQ     150    150       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036715.
FT   VAR_SEQ     394    823       SGKKSVNDKNLKKTVEDEDQDSEEEKDNDSYIKERSDIPSG
FT                                TSKHLQKKAKKQAKKQAKNQRRQQKIQGKVLHLNDICTIDH
FT                                PEDSEYEAEMSLQGEVNIKSNHISQEGVMHKEYCVNQKDLN
FT                                GQAKMIESVTDNQKSTEEVDMKNINMDNDLEVLTSSPTRNL
FT                                NGAYLTEGSNGEVDISNGFKNLNLNAALHPDEINIEILNDS
FT                                HTPGTKVYEVVNEDPETAFCTLANREVFNTDECSIQHCLYQ
FT                                FTRNEKLRDANKLLCEVCTRRQCNGPKANIKGERKHVYTNA
FT                                KKQMLISLAPPVLTLHLKRFQQAGFNLRKVNKHIKFPEILD
FT                                LAPFCTLKCKNVAEENTRVLYSLYGVVEHSGTMRSGHYTAY
FT                                AKARTANSHLSNLVLHGDIPQDFEMESKGQWFHISDTHVQA
FT                                VPTTKVLNSQAYLLFYERIL -> VRLLNLFYSSRFFFL
FT                                (in isoform 5). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_036716.
FT   VARIANT     141    141       Q -> H (in dbSNP:rs2274802).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_020388.
FT   MUTAGEN     205    205       C->S: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:10077596,
FT                                ECO:0000269|PubMed:11753566,
FT                                ECO:0000269|PubMed:17914355}.
FT   CONFLICT    141    141       Q -> E (in Ref. 8; AAG39290).
FT                                {ECO:0000305}.
FT   CONFLICT    297    297       Q -> R (in Ref. 3; BAG51175).
FT                                {ECO:0000305}.
FT   CONFLICT    348    348       K -> E (in Ref. 4; BAD96604).
FT                                {ECO:0000305}.
FT   CONFLICT    350    350       S -> P (in Ref. 4; BAD96401).
FT                                {ECO:0000305}.
FT   CONFLICT    480    481       EY -> DN (in Ref. 7; AAH30777).
FT                                {ECO:0000305}.
FT   HELIX        27     30       {ECO:0000244|PDB:2I50}.
FT   HELIX        33     40       {ECO:0000244|PDB:2I50}.
FT   STRAND       45     47       {ECO:0000244|PDB:2I50}.
FT   HELIX        49     52       {ECO:0000244|PDB:2I50}.
FT   TURN         63     65       {ECO:0000244|PDB:2I50}.
FT   STRAND       71     74       {ECO:0000244|PDB:2I50}.
FT   TURN         75     77       {ECO:0000244|PDB:2I50}.
FT   STRAND       80     82       {ECO:0000244|PDB:2I50}.
FT   STRAND       86     88       {ECO:0000244|PDB:2I50}.
FT   HELIX        90     96       {ECO:0000244|PDB:2I50}.
FT   STRAND      105    108       {ECO:0000244|PDB:2I50}.
FT   TURN        109    111       {ECO:0000244|PDB:2I50}.
FT   STRAND      114    116       {ECO:0000244|PDB:2I50}.
FT   TURN        117    120       {ECO:0000244|PDB:2I50}.
FT   STRAND      121    123       {ECO:0000244|PDB:2I50}.
FT   HELIX       130    142       {ECO:0000244|PDB:2I50}.
SQ   SEQUENCE   823 AA;  93570 MW;  C7D4175649BA3E31 CRC64;
     MGKKRTKGKT VPIDDSSETL EPVCRHIRKG LEQGNLKKAL VNVEWNICQD CKTDNKVKDK
     AEEETEEKPS VWLCLKCGHQ GCGRNSQEQH ALKHYLTPRS EPHCLVLSLD NWSVWCYVCD
     NEVQYCSSNQ LGQVVDYVRK QASITTPKPA EKDNGNIELE NKKLEKESKN EQEREKKENM
     AKENPPMNSP CQITVKGLSN LGNTCFFNAV MQNLSQTPVL RELLKEVKMS GTIVKIEPPD
     LALTEPLEIN LEPPGPLTLA MSQFLNEMQE TKKGVVTPKE LFSQVCKKAV RFKGYQQQDS
     QELLRYLLDG MRAEEHQRVS KGILKAFGNS TEKLDEELKN KVKDYEKKKS MPSFVDRIFG
     GELTSMIMCD QCRTVSLVHE SFLDLSLPVL DDQSGKKSVN DKNLKKTVED EDQDSEEEKD
     NDSYIKERSD IPSGTSKHLQ KKAKKQAKKQ AKNQRRQQKI QGKVLHLNDI CTIDHPEDSE
     YEAEMSLQGE VNIKSNHISQ EGVMHKEYCV NQKDLNGQAK MIESVTDNQK STEEVDMKNI
     NMDNDLEVLT SSPTRNLNGA YLTEGSNGEV DISNGFKNLN LNAALHPDEI NIEILNDSHT
     PGTKVYEVVN EDPETAFCTL ANREVFNTDE CSIQHCLYQF TRNEKLRDAN KLLCEVCTRR
     QCNGPKANIK GERKHVYTNA KKQMLISLAP PVLTLHLKRF QQAGFNLRKV NKHIKFPEIL
     DLAPFCTLKC KNVAEENTRV LYSLYGVVEH SGTMRSGHYT AYAKARTANS HLSNLVLHGD
     IPQDFEMESK GQWFHISDTH VQAVPTTKVL NSQAYLLFYE RIL
//
